Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cancer Genetics Inc (CGIX)

Cancer Genetics Inc (CGIX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Cancer Genetics, Inc. Announces Strategic Transactions

Note Payment Received from Interpace Diagnostics Group, Inc.

CGIX : 2.08 (-5.02%)
IDXG : 0.66 (+0.92%)
Cancer Genetics Announces 1-for-30 Reverse Stock Split

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced that it will effect a 1-for-30 reverse stock split of its outstanding...

CGIX : 2.08 (-5.02%)
Interpace Announces Closing of $13 Million Second Tranche Acquisition Financing from Ampersand Capital Partners

Interpace Diagnostics Group, Inc. (IDXG) announced today that it has closed on a $13 million Convertible Preferred Stock investment by Ampersand Capital Partners (Ampersand). This investment constitutes...

CGIX : 2.08 (-5.02%)
IDXG : 0.66 (+0.92%)
Datar Cancer Genetics Announces Positive Results With 42.9% Objective Response Rate, and 90.5% Disease Control Rate in Heavily Pre-treated Patients With Ultra-personalised Pan-cancer Treatment Protocol in the RESILIENT Trial

LONDON, MUMBAI, India and BAYREUTH, Germany, Oct. 9, 2019 /PRNewswire/ --

CGIX : 2.08 (-5.02%)
Datar Cancer Genetics Announces Positive Results With 42.9% Objective Response Rate, and 90.5% Disease Control Rate in Heavily Pre-treated Patients With Ultra-personalised Pan-cancer Treatment Protocol in the RESILIENT Trial

https://mma.prnewswire.com/media/1008171/Datar_Cancer_Genetics_Limited_Logo.jpg

CGIX : 2.08 (-5.02%)
Cancer Genetics Reports Second Quarter 2019 Financial Results and Provides Strategic Business Update

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced strategic, financial and operating results for the second quarter...

CGIX : 2.08 (-5.02%)
Cancer Genetics, Inc. Announces Strategic Transactions

Sale of BioPharma business to Interpace Diagnostics Group, Inc.

CGIX : 2.08 (-5.02%)
IDXG : 0.66 (+0.92%)
Interpace Diagnostics Acquires Cancer Genetics' Biopharma Services Business Supported by Investment from Ampersand Capital Partners

Conference Call to be Held Tomorrow, Tuesday July 16, 2019 @ 8:30 am ET

IDXG : 0.66 (+0.92%)
CGIX : 2.08 (-5.02%)
NHLD : 2.77 (+2.03%)
Innovate Biopharmaceuticals Expands Its Management team with the Addition of Ed Sitar as Its Chief Financial Officer

Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, today announced the appointment...

CGIX : 2.08 (-5.02%)
INNT : 0.81 (-7.38%)
LabCorp (LH) Closes Envigo Swap Deal, Expands in CRO Space

The conclusion of LabCorp's (LH) swap transaction will help enhance the company's Covance global nonclinical drug development capabilities with additional sites and resources.

DGX : 104.48 (+0.48%)
LH : 171.24 (+1.67%)
CGIX : 2.08 (-5.02%)
ICLR : 155.43 (+0.92%)
Propanc Biopharma Appoints Dr. Ralf Brandt to its Scientific Advisory Board

Propanc Biopharma, Inc. (OTCQB: PPCB) ("Propanc"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced...

CGIX : 2.08 (-5.02%)
PPCB : 0.3200 (unch)
Cancer Genetics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Strategic Business Updates

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through diagnostics, molecular markers and data solutions, today announced financial...

CGIX : 2.08 (-5.02%)
Demand for Cancer Treatment Remains High Despite Improving Survivability Rates

Deaths related to cancer dropped by 27% in the past quarter-century, meaning that 2.6 million fewer people died due to cancer during that time period, according to a report by the American Cancer Society....

SNETD : 0.3900 (+14.71%)
SNET : 0.0103 (+63.49%)
SESN : 1.14 (unch)
CGIX : 2.08 (-5.02%)
ABIO : 5.19 (-1.70%)
NAVB : 0.71 (-2.74%)
Cancer Genetics, Inc. Announces Pricing of $3.5 Million Public Offering of Common Stock

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced the pricing of a public...

CGIX : 2.08 (-5.02%)
Cancer Genetics Issues Letter to Shareholders

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today published a letter to shareholders...

CGIX : 2.08 (-5.02%)
Enbridge (ENB) Outpaces Stock Market Gains: What You Should Know

Enbridge (ENB) closed at $34.59 in the latest trading session, marking a +1.02% move from the prior day.

ENB : 37.62 (-1.16%)
ZACKS: Zacks.com featured highlights include: Stifel, Napco, Tricida and Under Armour

Zacks.com featured highlights include: Stifel, Napco, Tricida and Under Armour

SF : 61.41 (+0.79%)
NSSC : 30.33 (+0.48%)
UA : 15.61 (-0.70%)
TCDA : 37.19 (+8.55%)
ZACKS: Chipmakers QCOM and AVGO Bounce-Back After Rough Week

Recently, there has been significant turmoil surrounding the electronics component sector, specifically in wireless equipment and semiconductors. This was mostly due to the US blacklist of Huawei in May,...

GOOG : 1,315.46 (-0.40%)
QCOM : 87.96 (-2.79%)
MSFT : 150.39 (+0.03%)
AVGO : 317.70 (+2.13%)
AMKR : 13.00 (+0.78%)
INTC : 58.35 (+0.17%)
NVDA : 207.99 (-2.02%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI -1.62 , AIZ -0.39 , SBAC +3.83 , SO -0.27 , WELL +0.28
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar